Company/Division name | Nobelpharma America, LLC |
Parent company | Nobelpharma Co., Ltd. |
Type of work | Manufacturing |
Reshoring category: | Foreign Direct Investment |
Total number of jobs (added or to be added): | 20 |
Year reshoring announced: | 2020 |
Year reshoring implemented or to be implemented: | 2020 |
Domestically, the work will be done: | In-house |
Country(ies) from which reshored: | Japan |
City reshored to: | Bethesda |
State(s) reshored to: | MD |
If relevant, work nearshored to: | - |
Industry(ies): | Chemicals |
Product(s) reshored | pharmaceuticals |
What non-domestic negative factors made offshoring less attractive? | Regulatory compliance |
What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Proximity to customers/market, proximity to NIH and regulators |